Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Related Posts
Dao KT, Perera MX, Yip SA, Fox K. Managing a Rare Case of Methicillin-Resistant Staphylococcus aureus (MRSA) Holocord With Intravenous Antibiotics. Cureus. 2025 Mar 2;17(3):e79918.[...]
Kanin M, Slack M, Patel R, Chen KT, Jackson N, Williams KC, Grock S. Injectable Estradiol Dosing Regimens in Transgender and Nonbinary Adults Listed as[...]
Bandos H, Kim S, Henry NL, Hays RD, Calsavara VF, Luu M, Gresham G, Lu KY, Irvin WJ, Suga JM, Siddique S, Cecchini RS, Rogatko[...]